In a 10-year period, 1987-1997, there was a 14-fold increase in the rate of pneumococcal bacteremia in Sweden. Invasive pneumococcal isolates ( ), which were obtained from n p 1136 18 Swedish clinical microbiology laboratories from 1987 through 1997, and other national and international isolates were serotyped, and their clonal relationships were determined by molecular typing. The increase in invasive pneumococcal disease in Sweden during this period was associated particularly with an increase in isolates of serotypes 1 and 14. A 3-fold increase of type 14 was seen from 1987 through 1992, and a 10-fold increase of type 1 occurred from 1992 through 1997. One dominating penicillin-susceptible clone of type 14 was responsible for the increase of type 14 during the first 5 years. This clone also was found in Canada and the United States and was shown by multilocus sequence typing to correspond to a previously identified hyper-virulent clone. A novel penicillin-susceptible clone of type 1, which was not found among invasive isolates from 1987 or 1992, was responsible for the increase of serotype 1 during the last 5 years. These results illustrate the ability of virulent penicillin-susceptible pneumococcal clones to emerge and spread rapidly within a country.
molecular epidemiology of invasive pneumococcal isolates during these years. Here, we demonstrate that the successive appearance and spread of 2 particular clones of virulent pneumococci (of types 1 and 14) partly explain the increase of invasive disease in the Swedish population since 1987. The 2 clones were both penicillin susceptible, and their rapid increase in prevalence represents the first example of the rapid expansion of successful clones causing invasive disease that cannot be attributed to selection by antibiotic usage. The observed rapid fluctuation in the prevalence of different virulent clones has implications for the formulation of new pneumococcal vaccines.
Material and Methods

Bacterial Strains
Swedish invasive pneumococcal isolates. The present study is part of a continuous surveillance program of invasive pneumococcal isolates at the Swedish Institute for Infectious Disease Control (SMI) [8] . Pneumococcal isolates isolated by Swedish clinical microbiology laboratories are collected and are analyzed every 5 years, beginning in 1987. Invasive disease-causing pneumococcal isolates collected during 1987 ( ), 1992 ( ), and 1997 n p 148 n p 467 ( ) were included in this study. n p 521
International invasive isolates. Swedish type 14 isolates were compared with pneumococcal isolates of type 14 from an international multicenter study where pneumococcal isolates were collected from 354 patients with invasive disease from September 1993 to September 1995 at hospitals in Stockholm, Manchester (England), Barcelona (Spain), Huntington (West Virginia), and Halifax (Canada) [12] . Type 14 isolates were the most commonly encoun- Nasopharyngeal isolates from children at day care centers. Eighty-two pneumococcal nasopharyngeal isolates were obtained from 333 healthy children attending 8 different day care centers in Stockholm in 1995 [13] . Fourteen (17%) of the 82 isolates were of type 14 and were further analyzed.
Pneumococci with reduced susceptibility to penicillin. We also serotyped 664 isolates with reduced susceptibility to penicillin. The isolates were collected from different parts of Sweden during 1996 and 1998. Nineteen of the 52 type 14 isolates were studied for genetic relationship.
Bacteriology
All isolates studied were identified for species and were classified for serotype; most also were classified for antibiotype. Molecular typing was done on isolates belonging to type 14 (using the BOXpatterning method) and type 1 (using pulsed-field gel electrophoresis [PFGE]). Multilocus sequence typing (MLST) was done on a selected number of type 14 and type 1 isolates, enabling identification of previously identified clones present in international MLST databases.
Serotyping. Pneumococcal strains were identified by optochin sensitivity. All strains were serotyped at SMI by gel diffusion, using 46 type-or group-specific sera [14] obtained from the World Health Organization (WHO) Collaborating Center for Reference and Research on Pneumococci at Statens Seruminstitut (Copenhagen). Isolates that could not be typed or that belonged to a group that included 11 type were examined by the capsular reaction test [15] at the WHO Center.
Drug susceptibility testing. All isolates were tested for drug susceptibility, as described elsewhere [8] . In brief, an agar dilution method was used with serial 2-fold dilutions of each antibiotic incorporated in agar (PDM II Sensitivity Test Agar; Biodisk) supplemented with 5% horse blood. The minimum inhibitory concentration was defined as the lowest concentration of an antibiotic that did not permit visible growth.
The following antibiotics were used: benzyl penicillin (Astra), erythromycin (Abbott), clindamycin (Upjohn), tetracycline (Lederle), trimethoprim (Wellcome Foundation), and sulfamethoxazole (Hoffman-La Roche). Trimethoprim and sulfamethoxazole were tested in a ratio of 1:20.
Molecular Typing Methods
Two different molecular methods were used to characterize type 14 and type 1 isolates. We initially used the BOX-patterning method [16] , and all type 14 isolates were studied by use of this method.
For technical reasons, we recently changed to the PFGE method, by which all type 1 isolates were characterized.
BOX patterning. Of the 293 type 14 isolates from the abovementioned studies (table 1), 248 were characterized by BOX patterning, as described by Hermans et al. [16] . Chromosomal DNA, digested with PvuII restriction enzyme, was separated by use of agarose gel electrophoresis and was analyzed by Southern blot analysis, using a probe consisting of a 150-bp fragment containing a highly conserved DNA sequence from the intergenic regions of the chromosome (BOX). Isolates with a banding pattern of 190% similarity were defined as closely related and therefore were considered to be members of the same clone. The BOX patterns typically consisted of 130 bands; therefore, 90% similarity meant that the pattern could not differ by 13 bands.
PFGE. All 60 type 1 isolates from Sweden were analyzed with PFGE. The procedure was adapted from that described by Hermans et al. [16] . Chromosomal restriction fragments obtained by cleavage with restriction enzyme ApaI were embedded in agarose and were separated on a 1% agarose gel by PFGE performed for 22 h at 14ЊC at 6 V/cm in 0.5ϫ Tris-borate-EDTA, with pulse times of 2-30 s and an angle of 60Њ. After electrophoresis, the gel was stained with ethidium bromide for 30 min (1 mg/mL). Isolates that differed by not 13 bands were considered to be members of the same clone.
MLST. Thirty-six isolates belonging to types 14 and 1 were analyzed by use of MLST. These invasive isolates were selected on the basis of their isolation from different geographic areas. About half the strains analyzed by MLST were not assigned to the S14: 1 or S1:1 clones, as determined by use of BOX patterning or PFGE, respectively. The sequences of internal fragments of the 7 housekeeping loci used in the pneumococcal MLST scheme were determined for each isolate, as described elsewhere [17] . The alleles at each locus were assigned via the World Wide Web, using software at the MLST site (http://www.mlst.net); the 7 allele numbers (in the following loci order: aroE, gdh, gki, recP, spi, xpt, and ddl) define the allelic profile or sequence type (ST). The allelic profiles of the isolates were compared with those in the pneumococcal database at the MLST web site. The clustering of the isolates was represented as a dendrogram, using the matrix of pairwise differences in the allelic profiles, and the unweighted pair-group method with arithmetic averages.
Two-Dimensional PAGE (2-D PAGE)
Eight strains belonging to types 14 and 1 were characterized by use of 2-D PAGE. Pneumococci were harvested from batch cultures (medium) at an optical density of 0.8 and were centrifuged, and the pellets were dissolved in sterile water. Cells were disrupted by sonication, and cell debris was removed by centrifugation. Soluble protein was measured by a use of a kit (Bio-Rad Laboratories) and was stored at Ϫ70ЊC. Before loading on the first dimension, protein (40 mL) was mixed with 160 mL of buffer (9.9 M urea, 4% [vol/vol] Igepal CA630, 2.2% [vol/vol] ampholytes 3-10, 100 mM dithiothreitol, and
) and was stored at Ϫ70ЊC. Proteins were focused at 20ЊC on 180-mm IPG Drystrip (pH 4-7; Amersham Pharmacia Biotech), using the Multiphor II 2-D gel kit, according to the manufacturer's instructions. The second dimension was run on 12% SDS-PAGE gels, and proteins were visualized by silver staining. Chemicals were obtained from Sigma, except for Pharmalytes (Amersham Pharmacia Biotech). The BioImage 2-D-Analyzer 6.1 software (B.I. Systems) was used for spot matching, quantifying spot intensities, and calculating match statistics.
Results
Swedish Invasive Pneumococcal Isolates from 1987, 1992, and 1997
In total, 1136 pneumococcal strains from 1134 Swedish patients with invasive disease were characterized (table 1); 148 isolates were from 1987, 467 from 1992, and 521 from 1997. These isolates represented ∼50% of all invasive isolates reported in Sweden during these years (figure 1; for 1987, there was no reporting, which explains why the reported numbers for 1988 were used). The isolates for 1987 came from 8 laboratories, and those from 1992 and 1997 came from 18 and 16 laboratories, respectively. Sixty-one isolates were from cerebrospinal fluid (CSF): 12 were from 1987, 25 from 1992, and 24 from 1997. For 31 cases in which S. pneumoniae was isolated separately from both blood and CSF, only 1 of the 2 isolates was included in the study; each pair of isolates from the same patient always belonged to the same type. Two patients had 2 subsequent episodes of bacteremia, which were due to types 15A and 6B and types 11A and 23F, respectively.
More than 40 different serotypes were identified among the 1136 invasive isolates of S. pneumoniae obtained by Swedish clinical microbiology laboratories from 1987 through 1997 [8] . In descending order of frequency, the types most commonly encountered were 14, 7F, 9V, 4, 3, 1, 23F, and 6B, accounting for 63% of all isolates. Type 14 accounted for 13% of all isolates and was found most frequently in blood; however it accounted for only 3% of the 61 CSF isolates. Among the CSF isolates, 26 serotypes were found (range, 1-6 isolates/serotype), with types 3 and 23F being the major serotypes.
During the years studied, a shift in the prevalence of different serotypes occurred (figure 2) among invasive isolates. Type 14 isolates increased from 8% in 1987 to 18% in 1992 and then decreased to 11% in 1997. The frequency of type 1 isolates was low in 1987 (2%) and 1992 (1%) but increased to 10% in 1997.
Reduced susceptibility to penicillin was found in 2% of the isolates (range, 1%-3% for the 3 years) and showed no significant increase from 1987 through 1997. In 1997, 50% of these isolates belonged to serotype 9V, which is one of the most common serotypes among isolates with reduced susceptibility to penicillin in Sweden in 1997 (Henriques Normark et al., unpublished data).
The age profile of the 1134 patients from whom invasive pneumococcal isolates were obtained in 1987, 1992, and 1997 was similar for all 3 years. Seventy-one of the isolates (11 from 1987, 23 from 1992, and 36 from 1997) were obtained from children р15 years old. Of these isolates, 8 were from CSF, 55 from blood, 6 from both CSF and blood, and 1 from synovial fluid. Eleven serotypes were found, and the major serotypes, in descending order, were types 7F, 1, 6B, 14, and 23F. Type 1 isolates were found in isolates from 1997 only and accounted for 25% of invasive pneumococcal isolates obtained from children in that year.
Molecular Typing
We performed molecular typing, using the BOX-patterning method and PFGE, to investigate whether a particular number of clones was responsible for the increase of invasive types 14 and 1 pneumococcal isolates in Sweden from 1987 through 1997. We also used the BOX-patterning method to analyze the clonal relationship of type 14 isolates from 4 other studies. To explore whether clones identified in this study previously have been recognized internationally, we also analyzed a limited number of isolates by use of MLST.
Type 14 isolates. Of 153 type 14 invasive pneumococcal isolates obtained during 3 years (1987, 1992 , and 1997) in Sweden, 143 were analyzed by BOX patterning; 141 of the isolates were susceptible to penicillin, and 2 had decreased susceptibility to penicillin. Of these, 86% were highly related (190% similarity), indicating that they were members of the same clone (hereafter referred to as clone S14:1; table 1). Of the 97 isolates from 1987 and 1992, 88 (91%) belonged to S14:1. Of the remaining 9 isolates, 5 had an identical pattern, indicating that they belonged to yet another specific clone. The other 4 isolates had different and individual patterns. Of the 56 invasive type 14 isolates from 1997, 35 (76%) of 46 tested belonged to clone S14:1 (table 1) .
Sixteen type 14 isolates also were analyzed by MLST (table 2; figure 3 ). All 7 S14:1 isolates showed an identical MLST allelic profile (7-5-1-8-14-11-14; ST124), which corresponded to that of a major serotype 14 clone previously associated with invasive disease in several countries, including Australia, Canada, The Netherlands, Finland, Sweden, and Denmark [17] . An additional 6 of the type 14 isolates had the same allelic profile, although BOX patterning revealed 13 differing bands. Two further type 14 isolates (PJ499 and PJ581) were related closely to the major clone, differing from ST124 at only 1 of the 7 loci, although box patterning placed them outside the S14:1 clone. The remaining type 14 isolate (PJ75) was completely unrelated to the S14:1 clone, as judged by both MLST and BOX patterning. This isolate was closely related to the England 14 -9 clone. The S14:1 clone also was found in isolates obtained from Canada and the United States (table 1 ). In addition, it was found in a high proportion among isolates from the nasopharynx of patients and healthy carriers (children attending day care centers) in Sweden (table 1). All these isolates were susceptible to penicillin. The S14:1 clone was not found among isolates with a reduced susceptibility to penicillin ( (table  3) . This clone was not found among isolates from the previous years. The second most common clone, S1:2, accounted for 25% (13/51) of the isolates from 1997, but only 1 isolate of this clone was found in each of the years 1987 and 1992. No particular clone predominated among the 9 type 1 isolates from 1987 and 1992. Of the 9 type 1 isolates from children !16 years old, 5 belonged to clone S1:1, 3 to clone S2:1, and 1 to clone S1:3; all were isolated in 1997.
Of 20 type 1 isolates examined by MLST, 11 showed an identical allelic profile (12-8-13-5-16-4-20; ST306; table 2; figure  3 ). Ten of these 11 isolates belonged to the S1:1 clone, as defined by PFGE. No isolates in the MLST database had the same allelic profile as the S1:1 clone; the most similar isolates, which were all serotype 1, differed at 2 of the 7 loci. Four of the remaining isolates (PJ537, PJ1084, PJ1098, and PJ1160) appeared to be more distantly related to the major S1:1 clone, differing at 3 of the 7 loci. These isolates were not assigned to the S1:1 clone by PFGE. The remaining 5 isolates (PJ23, PJ897, PJ302, PJ337, and PJ351) showed completely different MLST profiles and PFGE patterns from the major clone.
Comparison of Protein Expression Pattern from Clonal and Nonclonal Strains
We analyzed the 2-D PAGE pattern of 2 isolates (PJ176-14 and PJ341-14) belonging to the S14:1 clone and compared the patterns to those of a type 14 strain (PJ274-14) assigned to the S14:1 clone by MLST (but not by BOX patterning) and of a figure 3 . BOX, BOX patterning; PFGE, pulsed-field gel electrophoresis; SLV, single-locus variant (i.e., the allele at 1 of the 7 loci used in MLST differs). type 14 isolate (PJ75-14) showing a completely different MLST profile and BOX patterning than the S14:1 clone. Likewise 2 isolates (PJ1116-1 and PJ1178-1) belonging to the S1:1 clone were compared with 2 other type 1 isolates (PJ897-1 and PJ1098-1) exhibiting MLST profiles and PFGE patterns different than the major type 1 clone. One section from each 2-D PAGE was compared (figure 4). The 2 isolates belonging to the S14:1 clone and the 2 belonging to the S1:1 clone were more similar to each other than to any of the other isolates. Of interest, isolate PJ274-14, which was assigned to the S14:1 clone by MLST but not by BOX was less similar to the 2 isolates assigned to the clone by both MLST and BOX patterning than were the latter isolates to each other. However, 2-D PAGE revealed that PJ274-14 clearly was highly related to the S14:1 clone. This isolate, unlike the members of the S14:1 clone, had a reduced susceptibility to tetracycline and therefore may be a variant member of the S14:1 clone that has emerged via antibiotic selection.
Discussion
During the period 1987-1992, we noticed a 3-fold increase in the incidence of pneumococcal bacteremia in Sweden [8] . About one-fourth of this increase was attributable to infections caused by type 14 pneumococcal strains. The incidence of disease continued to increase from 1992 through 1997, partly because of a 10-fold increase in type 1 isolates.
Although all of the 90 different capsular types of S. pneumoniae appear to be capable of causing invasive diseases in humans, the different types are identified with extremely different frequencies [18] . This was exemplified during a study comprising 113,000 strains collected worldwide; the 60 rarest . A linkage distance of 0.14 corresponds to a difference at 1 of the 7 loci used in MLST. The cluster of isolates that were identical by MLST and that correspond to the S1:1 and S14:1 clones are shown. Names of the isolates are given and followed by a hyphen and their serotype. types accounted for only 8.5% of isolates, whereas the 10 most prevalent ones made up 62% of the total [1] . Thus, a limited number of types are responsible for most cases of invasive disease. However, the rank order of the 10 most prevalent types has differed significantly during the 20th century. In the beginning of the 20th century, types 1, 2, and 3 together accounted for up to 75% of the bacteremic cases in the United States and Europe [19] [20] [21] [22] . Today, types 1 and 2 are uncommon in Western countries [8, 11, [23] [24] [25] [26] , and neither has been included in the newly licensed 7-valent pneumococcal conjugate vaccines. Type 3 remained as one of the most prevalent types until a few decades ago, when it decreased in frequency in many countries [11, [23] [24] [25] [26] , as seen also in Sweden [8] . Instead, type 14 has been the most prevalent type in many areas, comprising 110% of the isolates [24, 25, 27 ], yet accounting for only a few percent during 1950-1960 [5, 26] . The reasons for the substantial shifts in serotype prevalence noted during the last century are essentially unknown. Among Swedish invasive isolates in this study, we observed that the frequency of type 14 increased from 8% in 1987 to 18% in 1992, accounting for almost one-fourth of all isolates in patients у65 years old in 1992. From 1992 through 1997, the frequency of type 14 decreased, whereas the number of isolates of types 1 and 4 increased.
Using molecular typing methods, we found that 91% of the type 14 isolates that cause invasive disease in Sweden during 1987 and 1992 were identical or almost identical, as determined by the BOX-patterning method. Accordingly, we consider these type 14 isolates to belong to a single clone (S14:1); thus, ∼17% of all invasive pneumococcal disease in Sweden in 1992 belonged to a single clone. In 1997, the predominance of type 14 had decreased, but 76% of the isolates still belonged to S14:1. The same type 14 clone also was found to predominate among nasopharyngeal isolates from adults and from children attending day care centers in the Stockholm area in 1995. All invasive isolates belonging to the S14:1 clone were sensitive to penicillin, and 190% also were susceptible to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole, which suggests that the expansion of this clone has not been driven by antibiotic usage. Instead, it seems to have properties that promote both invasive disease and carriage in adults and children. Also, a spread of the clone was seen particularly in one of the day care centers, which suggests a high transmission capability.
Isolates belonging to clone S14:1 also were found in 2 patients from Canada and the United States, which suggests that this clone has spread globally. Despite the significant increase of type 14 isolates in many Western countries, including the United States, most of the non-Swedish isolates in this study belonged to clones other than S14:1. However, according to MLST, the type S14:1 clone identified among invasive Swedish isolates previously has been associated with invasive disease in several countries on 3 continents (including the countries Australia, Canada, The Netherlands, Finland, Sweden, and Denmark) [17] . There was a satisfying consistency between the 2 typing methods used, MLST and BOX patterning, although BOX patterning appeared to be more discriminatory. Isolates that are identical or almost identical by MLST should probably be regarded as members of a single clone, from which minor variants have emerged and caused the differences seen with BOX patterning and with 2-D PAGE. 2-D PAGE is a method that not only reveals expression of specific proteins but also indicates differences in isoelectric point among allelic variants of the same protein emanating from mutations that cause amino acid substitutions within a given protein. It is a sensitive method to detect differences among clinical isolates. MLST uses variation in housekeeping loci that accumulates relatively slowly and is capable of showing the relatedness of isolates that have accumulated sufficient variation to be considered unrelated, using methods that index variation that accumulates more rapidly (e.g., PFGE or BOX patterning).
From 1992 through 1997, type 1 isolates increased from 1% to 10%. Such an increase also was noticed when studying just the isolates from children. Hence, 25% of isolates from children in 1997 were of type 1, whereas no type 1 isolates from children were found in 1987 and 1992. Molecular typing of all type 1 isolates showed that 1 clone predominated (clone S1:1) in 1997 and that this clone was not found among type 1 isolates from 1987 and 1992. This suggests either the introduction and spread of a new virulent clone causing invasive disease in Sweden or the dramatic expansion of a minor preexisting clone. In contrast, the second most common clone of type 1 in 1997 (clone S1:2) also was found among isolates from 1987 and 1992. Type 1 isolates were found in isolates from children during 1997 only, and included clones S1:2 and S1:3, also indicating a clonal spread among children.
In contrast to the prevalence of clone S14:1 among healthy carriers, no type 1 isolates were found among 246 pneumococcal isolates from children at 16 day care centers in the Stockholm area during 1997-1998 (Henriques Normark et al., unpublished data). S1:1 was shown to be a novel clone with an MLST allelic profile previously not observed. This is consistent with our epidemiologic finding that this clone has emerged recently. All isolates belonging to the S1:1 clone were susceptible to all antibiotics tested, which suggests that the expansion of this clone in Sweden also has occurred without antibiotic-driven selection.
Sixty-one of the 1136 isolates were obtained from CSF. As many as 26 serotypes were found among these isolates, with just a few isolates per serotype, which suggests that the spread of specific clones is less significant among isolates that cause meningitis. Rather, many different types seem to be able to cause meningitis, implying that host factors may be more important in the development of pneumococcal meningitis, compared with septicemia. Of interest, the increase in reported invasive Swedish isolates was solely attributable to an increase in isolates from blood and not from CSF (figure 1). It seems that this increase was primarily due to an expansion of a limited number of clones, again suggesting that clonal selection occurs among isolates that cause bacteremia but not among those that cause meningitis. Also, our data suggest that there may be an association between transmission ability and carriage of certain clones among healthy individuals and their occurrence in septicemia but not between carriage and meningitis.
Clones of antibiotic-resistant Streptococcus pneumoniae have been shown to spread extensively with the expansion of a few clones largely responsible for the rapid worldwide emergence of penicillin resistance [28, 29] . One example is a multiresistant 6B clone originating from Spain that accounted for 20% of all pneumococcal isolates in Iceland for several years [30] . Most attention has been focused on the spread of drug-resistant clones, in which rapid expansion is likely to be driven by antibiotic selection. Our study demonstrates that antibiotic selection is not necessary to drive the rapid emergence of pneumococcal clones; penicillin-susceptible invasive clones also may increase rapidly and spread over a large geographic area. We also show that there is a fluctuation in the spread of virulent clones at different time points. For example, during 1987-1992, a dramatic increase of a type 14 clone (S14:1) was seen, and, from 1992 through 1997, a type 1 clone (S1:1) emerged.
Of interest, in 1987 and 1992, when type 1 represented a minor serotype, no particular clone was dominating, which suggests that minor serotypes may be represented by a large number of individual clones. The mechanism by which specific clones become dominant is not clear. Carriage among healthy individuals may be an important factor that influences the occurrence of clones among invasive isolates. Also, immunoselection might enhance the rate by which novel clones belonging to rare serotypes (not covered by the vaccine in use) are selected and expand in the pneumococcal community [18] . Hence, because of large clonal fluctuations over time, vaccine coverage may vary dramatically over time and require constant vaccine modifications in different countries for optimal coverage [31, 32] .
The rapid emergence of a virulent clone of serotype 1 in Sweden is particularly worrisome because this serotype is rare in the United States and Europe and thus is not included in the recently licensed 7-valent conjugate pneumococcal vaccine. After vaccination, relatively subtle effects on the transmission of virulent clones within some nonvaccine serotypes (e.g., the S1:1 clone) may have significant and unpredictable effects on the incidence of invasive disease [33] . Adequate surveillance of the pneumococcal serotypes and clones responsible for invasive disease therefore will be crucial to ensure that the vaccine coverage in individual regions remains sufficient.
